New Treatments Activated in Clinical Trial at Henry Ford Cancer Institute

In a global clinical trial, GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), Henry Ford Cancer Institute is the first to activate two new treatments for glioblastoma. The GBM AGILE trial allows for global collaboration …